2. INVESTOR PRESENTATION | 2015 CANCER GENETICS, INC. | WWW.CANCERGENETICS.COM | @CANCER_GENETICS 2
This presentation contains forward-looking statements within the meaning of the Private Securities Litigation
Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in research,
technology, clinical development and potential opportunities for Cancer Genetics, Inc. products and services, along
with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management
constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to,
statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be
considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including,
without limitation, risks inherent in the development and/or commercialization of potential products, risks of
cancellation of customer contracts or discontinuance of trials, risks that anticipated benefits from acquisitions will
not be realized, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future
capital, maintenance of intellectual property rights and other risks discussed in the Cancer Genetics, Inc. Forms 10-
K for the year ended December 31, 2014 and 10-Q for the quarter ended June 30, 2015 along with other filings with
the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof.
Cancer Genetics, Inc. disclaims any obligation to update these forward-looking statements.
FORWARD-LOOKING STATEMENT
3. INVESTOR PRESENTATION | 2015 CANCER GENETICS, INC. | WWW.CANCERGENETICS.COM | @CANCER_GENETICS 3
CANCER GENETICS, INC. INVESTOR HIGHLIGHTS
Uniquely Positioned
to Address Global
Market Opportunities
in Oncology
3 ACQUISITIONS
$458B GLOBAL ONCOLOGY
SPENT BY 2030
Unique &
Proprietary Portfolio
of Genomic
Tests & Panels
8 PATENTS
9 TESTS LAUNCHED
Strong & Growing
Relationships with
Leading Biotech &
Pharma Partners
+650%
BIOPHARMA
CONTRACTS
2012-2015
18 RESEARCH
COLLABORATIONS
Innovation &
Expertise Driven
by Key
Collaborations
100+ CUMULATIVE YEARS
OF EXPERIENCE
World-Class
Management
Team & Scientific
Advisory Board
55% AAGR
Diversified &
High Growth
Revenue
Streams
4. INVESTOR PRESENTATION | 2015 CANCER GENETICS, INC. | WWW.CANCERGENETICS.COM | @CANCER_GENETICS 4
OUR MISSION IS TO BE THE ONCOLOGY DIAGNOSTICS
PARTNER OF CHOICE FROM
PARTNERING WITH
LEADING RESEARCH
INSTITUTIONS TO
DEVELOP NEW INSIGHTS
& INNOVATIONS
PROVIDING EXPERTISE
& EXECUTION TO
BIOPHARMA
COMPANIES FOR
IMPROVED OUTCOMES
RESEARCH
CLINICAL
TRIALS
PATIENT
CARE
DELIVERING CRITICAL
GENOMIC INSIGHTS FOR
MEDICAL PROFESSIONALS
TO PERSONALIZE PATIENT
TREATMENTS
5. INVESTOR PRESENTATION | 2015 CANCER GENETICS, INC. | WWW.CANCERGENETICS.COM | @CANCER_GENETICS 5
UNIQUELY POSITIONED TO ADDRESS THE MACRO-TRENDS
IN TODAY’S ONCOLOGY MARKET ENVIRONMENT
Increasing global need for improved oncology
diagnosis & management1
Committed to a global footprint
focused on innovation and state-of-
the-art infrastructure and people
Growing awareness and adoption of
genomic testing by both clinicians and patients2
Highly developed and trained sales
force of 20+ that is uniformly focused
on educating and serving clinicians
Majority of cancer clinical trials now
incorporate biomarkers and genomic tests3
Fastest growing area of our business is
focused on incorporating biomarkers into
trials for game-changing oncology drugs
Test costs continue to decrease with
newer technologies and improved analytics4
Our focus is the disease and on patient
outcomes and are platform agnostic –
which makes us uniquely flexible
Industry consolidation seeks to leverage
economies of scale and expand marketing reach5
Consolidation in our industry is critical to
achieving scale, creating a durable
business and impacting more patients
6. INVESTOR PRESENTATION | 2015 CANCER GENETICS, INC. | WWW.CANCERGENETICS.COM | @CANCER_GENETICS 6
OUR MARKET OPPORTUNITY IS GLOBAL & GROWING
CLINICAL$6B
$2.5B BIOPHARMA
UNITED STATES
$1B CLINICAL
$0.4B BIOPHARMA
INDIA
$1B BIOPHARMA
CHINA
NEW CANCER PATIENTS DIAGNOSED
GLOBALLY
14.1M
IN THE USA:
1.6M
50%
CAN BE
IMPACTED BY
CGI’S PORTFOLIO
IN INDIA:
1M
47%
CAN BE
IMPACTED BY
CGI’S PORTFOLIO
PROJECTED COST OF
CANCER CARE BY 2030
$458B
AVERAGE COST OF THERAPY
PER CANCER PATIENT
$135K
2015 COST OF CANCER CARE
R&D EXPENDITURE IN BIOPHARMA
GLOBALLY
$115B
SPENT IN THE USA
$49B
SPENT GLOBALLY
IN ONCOLOGY
$26B
Data from CGI 2014 Annual Report:
http://content.stockpr.com/cancergenetics/media/eb1e21488c08d043081d6607733a26f0.pdf
7. INVESTOR PRESENTATION | 2015 CANCER GENETICS, INC. | WWW.CANCERGENETICS.COM | @CANCER_GENETICS 7
OUR MARKET SEGMENTS & STRATEGY
COMMERCIALIZATION STRATEGYTARGET MARKET SEGMENTS MARKET OPPORTUNITY
Community Hospitals
Regional Cancer Centers
Oncologists & Pathologists
Continue growing sales force that calls on hospitals &
regional labs
Partner with key regional cancer centers and hospitals
Focus on both education and collaboration to
differentiate against the “cookie-cutter” labs
Pharmaceutical &
Biotechnology Companies
Leverage clinical infrastructure and proprietary product
portfolio for testing services that support clinical trials
Expanding the ales emphasis of disease-focused
program
Universities &
Research Centers
Collaborate to create/validate unique genomic panels
and proprietary tests
Accelerate launch of large scale studies to support test
adaption & validation (data)
Oncospire Genomics Joint Venture with Mayo Clinic
Emerging Markets
India | China
Partner with leading local cancer care providers and
hospitals to provide Focus::Hotspot™ and FHACT® in India
Invest in unique sales team and infrastructure to serve
markets where nearly a 1/3 of new cancer cases are
developing
Partner with select Biopharma clients that need market
access
4K+ U.S. HOSPITALS
28K+ ONCOLOGISTS &
PATHOLOGISTS
3K+
U.S. CLINICAL
TRIALS FOR ALL
CANCER TYPES
200+
RESEARCH
CENTERS
IN THE U.S.
1M+ INDIA - CANCER
CASES/YEAR
3.1M+ CHINA - CANCER
CASES/YEAR
~30% OF TOTAL ANNUAL
GLOBAL CANCER CASES
8. INVESTOR PRESENTATION | 2015 CANCER GENETICS, INC. | WWW.CANCERGENETICS.COM | @CANCER_GENETICS 8
ACQUISITIONS
Response Genetics, Inc. (Pending 2015)
Leading solid tumor testing franchise with critical clinical
content in Lung, Colorectal, Skin, and Brain cancers
Strong commercial presence in Western & Southeast
U.S. with over 3,000 customers
Only FDA approved and Medicare reimbursed test for
tumors of unknown origin – TOO™
Bioserve, India (August 2014)
First company to provide DNA synthesis, DNA
sequencing, & related services in India
Customers and clients include CCMB, ICMR, CSIR
institute, and several major biopharma companies
ISO 9001:2015 (185417-205-AQ-IND-RvA)
Gentris, Inc. (July 2014)
Global provider of pharmacogenomics, NGS, genotyping,
and biorepository services to Biopharma
U.S. FDA-compliant laboratory in Zhanjiang Hi-Tech
Park, Shanghai, China
KEY M&A CRITERIA
Capabilities
Geographic Footprint
Customers & Clients
Unique Content in Cancer
Culture & Human Capital
GLOBAL FOOTPRINT
UNITED STATES
RESPONSE
GENETICS
NC
NJ
INDIA
CHINA
ACTIVE ACQUISITION STRATEGY TO EXPAND GROWTH &
ESTABLISH SIGNIFICANT MARKET SHARE GLOBALLY
18,000 sq. ft.
28,000 sq. ft.
14,000 sq. ft.
3,000 sq. ft.
TOTAL 90,000 sq. ft.
27,000 sq. ft.
9. INVESTOR PRESENTATION | 2015 CANCER GENETICS, INC. | WWW.CANCERGENETICS.COM | @CANCER_GENETICS 9
RESPONSE GENETICS, INC. ACQUISITION HIGHLIGHTS
$8-9M
IN CLINICAL
& HOSPITAL
TESTING
NEW CLINICAL REVENUE
$2-3M
EXPECTED FROM
NCI’S ALCHEMIST TRIAL &
BIOPHARMA CUSTOMERS
ADDITIONAL BIOPHARMA
REVENUE & PARTNERS
GEOGRAPHIC REACH
STRONG COMMERCIAL
PRESENCE IN THE
WESTERN & SOUTH EASTERN
U.S.A.
SALES FORCE PRESENCE
APPROXIMATELY
14 SALES
PROFESSIONALS
COMPLEMENTARY
ONCOLOGY PORTFOLIO
8 of 10solid tumor types
TISSUE OF ORIGIN™: ONLY
FDA-CLEARED TEST OF ITS
TYPE, MEDICARE APPROVED
EXPERTISE IN
SOLID TUMOR
FOCUSED TESTS
$10-12M
EXPECTED
OVER NEXT
12 MONTHS
ADDITIONAL REVENUE
CONTRIBUTION
10. INVESTOR PRESENTATION | 2015 CANCER GENETICS, INC. | WWW.CANCERGENETICS.COM | @CANCER_GENETICS 10
IMPROVING ONCOLOGY CLINICAL TRIAL DEVELOPMENT
WITH UNIQUE GENOMIC INSIGHT
CONTRACTS WITH
PHARMACEUTICAL
COMPANIES INCLUDING
GILEAD, ASTRA ZENECA, & ROCHE
7 10OF THE
TOP
70+ CLINICAL
TRIALS
ACTIVELY PROVIDING
TESTING, GENOMIC SERVICES,
AND BIOMARKER SUPPORT
FOR
$0
$10
$20
$30
+650%
INCREASE
IN SIGNED
CONTRACTS
& POTENTIAL
REVENUES WITH
BIOPHARMA
CUSTOMERS
2012 TO 2015
Approximate expected future revenues under signed contracts with biotechnology & pharma customers
for testing & services to support currently planned clinical trials.
2012 2013 2014 2015 YTD
MILLIONS
VALUE OF
BIOPHARMA
CONTRACTS
$32
$25
$8
$4
11. INVESTOR PRESENTATION | 2015 CANCER GENETICS, INC. | WWW.CANCERGENETICS.COM | @CANCER_GENETICS 11
ICON PARTNERSHIP & STRATEGIC ALLIANCE
• Partnership w/ ICON offers comprehensive oncology lab testing & solutions for global biopharma
• Tests and services offered by CGI through ICON will be branded as “Powered by CGI”
• Complementary capabilities for cross and upselling to biotech and pharma customers
• CGI capabilities address the needs of ICON’s 900+ oncology studies from Phase I-IV
• Cross training of global sales forces & scientific affairs teams scheduled through 2015-16
• CGI has already realized quick wins with both joint accounts and joint selling efforts
• CRO industry leader with $1.5B in net annual revenue & 11,000+ employees
• Biopharma outsources ~45% of R&D, growing to ~50% by 2016
• Top 6 CROs have 55% share, consolidating to ~60% share by 2015
• ~30% of ICON revenue is from oncology, in line with industry R&D spend
• >33% of drugs in clinical development use biomarkers in trials
UNLOCKING SIGNIFICANT BUSINESS SYNERGIES & ACCELERATING BIOPHARMA REVENUE
12. INVESTOR PRESENTATION | 2015 CANCER GENETICS, INC. | WWW.CANCERGENETICS.COM | @CANCER_GENETICS 12
OUR EXTENSIVE ONCOLOGY PORTFOLIO IS CENTERED ON
FOUR MAJOR PRINCIPLES
III. INNOVATIVE
Focus on UnMet and
Critical Disease States
Chronic Lymphocytic
Leukemia
Renal Cancer
Lymphoid
Malignancies
Cervical Cancer
Lung Cancer
Pharmacogenomics
Germline & Somatic
I. COMPLETE
Comprehensive
& Agnostic
Methodologies
Next Generation
Sequencing (NGS)
Array-CGH
PCR/Sequencing
FISH
IHC
Flow Cytometry
II. COLLABORATIVE
Developed with
Though Leaders
Multiple Myeloma &
Lung Cancer
OncoSpire Genomics >
Mayo Clinic
Cervical Cancer
FHACT® >
National Cancer Institute
Myeloid Cancers
Focus::Myeloid™ >
Columbia University
IV. ACTIONABLE
Impacting Patient Care
Community Hospitals
Cancer Centers
Oncologists
Pathologists
Improving Clinical
Trials
Pharmaceutical and
Biotech companies
13. INVESTOR PRESENTATION | 2015 CANCER GENETICS, INC. | WWW.CANCERGENETICS.COM | @CANCER_GENETICS 13
UNIQUE, PROPRIETARY PORTFOLIO OF GENOMIC
TESTS & PANELS
* Oncospire Genomics: a joint venture with Mayo Clinic
RESEARCH &
DISCOVERY
CLINICAL
DEVELOPMENT
COMMERCIAL
DEVELOPMENT
MARKET
ENTRY
FOCUS::MYELOID™ (IN COLLABORATION WITH ILLUMINA)
FOCUS::LYMPHOID™
FOCUS::CLL™ (CLL/SLL)
MATBA® FOR B-CELL CANCERS (CLL, DLBCL, FL, MCL)
TEST IN MARKET
TEST IN MARKET
4 TESTS IN MARKETBLOOD
CANCERS
Late 2015
MULTIPLE MYELOMA
FOLLICULAR LYMPHOMA
LUNG CANCER
ONCOSPIRE
GENOMICS*
TBD
Late 2015
Late 2015
TISSUE OF ORIGIN™ (RESPONSE GENETICS) TEST IN MARKET
FOCUS::RENAL™
UROGENRA®-KIDNEY TEST IN MARKET
FHACT® CERVICAL TEST IN MARKET
FOCUS::CANCER HOTSPOT™ (RESEARCH INDIA, BIOPHARMA US) TEST IN MARKET
SOLID
TUMORS
Early 2016
HEREDITARY Late 2015
HEREDITARY CANCER PANEL
COMPREHENSIVE PHARMACOGENOMICS (PGX) PANEL
TBDFOCUSED ON WOMEN’S HEALTH
14. INVESTOR PRESENTATION | 2015 CANCER GENETICS, INC. | WWW.CANCERGENETICS.COM | @CANCER_GENETICS 14
MATBA® DRIVES IMPROVED INSIGHT & MANAGEMENT FOR
CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS
CGI SOLUTION
38% of cases are
favorable falling
under "watch &
wait" approach
8% of unfavorable
cases missed by
FISH are detected by
MatBA®-CLL/SLL
23%
39%
38%
Favorable
Intermediate
Unfavorable
MatBA®-CLL/SLL is CLIA & NYS licensed to stratify
patients into 3 distinct risk groups using 20 biomarkers:
CLINICAL NEED
Standard FISH testing for CLL is based on
4 biomarkers & stratifies patients into 2 risk groups:
Favorable/
Intermediate
(no distinction)
Unfavorable
FISH
Testing
85%
15%
15. INVESTOR PRESENTATION | 2015 CANCER GENETICS, INC. | WWW.CANCERGENETICS.COM | @CANCER_GENETICS 15
UROGENRA®-KIDNEY GUIDES MANAGEMENT
& APPROPRIATE TREATMENT SELECTION
• Patients with renal masses often undergo
unnecessary nephrectomy for accurate
diagnosis & experience delay in treatment
• Over 15% of needle biopsies of renal masses are
rendered non-diagnostic
CLINICAL NEED
• UroGenRA®-Kidney assesses 16 biomarkers in a
single assay
• Provides accurate diagnosis guiding appropriate
clinical management and treatment strategies
(benign vs malignant; malignant subtype)
• Reduction in number of highly invasive
procedures & time to treatment initiation
CGI SOLUTION
PROPRIETARY DIAGNOSTIC ALGORITHM
>600 RCC MALIGNANT
SUBTYPES
in-silico: SNP
>100 MALIGNANT & BENIGN
RENAL NEOPLASMS
in-house: aCGH & FISH
RETROSPECTIVE IN-HOUSE FFPE
VALIDATION (n>190)
100%DIAGNOSTIC
YIELD 97%DIAGNOSTIC
SENSITIVITY
to distinguish
benign/malignant
93%SENSITIVITY
to distinguish
malignant RCC
subtypes
PROSPECTIVE ONGOING PERCUTANEOUS
CORE NEEDLE BIOPSY (n>190)
DEMONSTRATED ABILITY TO DIAGNOSE PATHOLOGICALLY
“UNCLASSIFIABLE” BIOPSIES PRIOR TO SURGICAL INTERVENTION
16. INVESTOR PRESENTATION | 2015 CANCER GENETICS, INC. | WWW.CANCERGENETICS.COM | @CANCER_GENETICS 16
FHACT® FITS DIRECTLY INTO TODAY’S
CERVICAL CANCER SCREENING WORKFLOW
55MPAP SMEARS
3.5MUNCLEAR/
ABNORMAL
2MBIOPSIES
13KCASES OF
CANCER
• Today, all HPV+ women with abnormal
Pap results are referred for
colposcopy
• Several cervical cancer tests are
available but the need for less invasive
and better informed treatment exists
CLINCAL NEED
• FHACT® helps triage before colposcopy
• Non-invasive test performed on
remnant liquid cytology – no
resampling is necessary which means
no additional doctor visit
• Fewer women referred for colposcopy
reducing healthcare costs & patient
anxiety
CGI SOLUTION
Today, all these women are
referred for colposcopy
PROGRESS to a higher grade and
increased risk for cancer within
10-30 years of the infection
REGRESS within 2 years of
the infection
Not referred for
colposcopy
FHACT®
Results:
Normal
Referred for
colposcopy
FHACT®
Results:
Abnormal
~90% ~10%
HPV+ women with abnormal or unclear liquid-based cytology
18. INVESTOR PRESENTATION | 2015 CANCER GENETICS, INC. | WWW.CANCERGENETICS.COM | @CANCER_GENETICS 18
FOCUS::LYMPHOMA™ – TARGETED, DISEASE-FOCUSED PANEL
DLBCL
MCLFL
31 MARKERS
25 MARKERS 11 MARKERS
89 18
25
1
FOCUS::LYMPHOMA™
220 genes of interest for lymphomas
LYMPHOMA PANEL COMPARISON
Focus::Lymphoma™ vs. FoundationOne Heme
110
110 MARKERS 296 MARKERS
Focus::Lymphoma™
Panel
FoundationOne
Heme Panel
• Only 110 of the 220 Focus::Lymphoma™ panel genes are
included in the FoundationOne Heme panel
• Many important sets of genes are missing from
FoundationOne Heme including:
• BCR Signaling genes (x4)
• PI3K Pathway genes (7)
19. INVESTOR PRESENTATION | 2015 CANCER GENETICS, INC. | WWW.CANCERGENETICS.COM | @CANCER_GENETICS 19
ONCOSPIRE GENOMICS
JOINT VENTURE BETWEEN CANCER GENETICS & MAYO CLINIC
• Joint venture based in Rochester, MN
• Goal: to develop tests that will become the gold standard in
diagnosing and managing patients with selected disease targets
• Diseases with known clinical dilemmas were selected and
informed by clinicians in the Mayo Clinic network
• OncoSpire has the rights to druggable targets that are discovered
SELECTED PROJECTS PIPELINE:
200,000 NEW CASES
PER YEAR MULTIPLE MYELOMA
LUNG CANCER
FOLLICULAR LYMPHOMA
1.6M NEW CASES
PER YEAR
RESEARCH& DISCOVERY CLINICALDEVELOPMENT COMMERCIAL DEVELOPMENT LAUNCH &MARKET ENTRY
Q4 2015 Expected Launch
20,920 NEW CASES
PER YEAR
20. INVESTOR PRESENTATION | 2015 CANCER GENETICS, INC. | WWW.CANCERGENETICS.COM | @CANCER_GENETICS 20
Disease Target Collaboration Highlights
Beth Israel Deaconess Medical Ctr DLBCL Biomarker-based outcome prediction
Cleveland Clinic Kidney Cancer Genomic marker validation
Columbia University AML, MDS, and Myeloid Cancers NGS panel development
Dana-Farber Cancer Institute CLL CLL outcome scheme validation
Georgia Regents University DLBCL Diagnosis, prognosis & management
Hackensack University Medical Ctr CLL Further validation of MatBA®-CLL regions
Kamineni Hospital, India Cervical Cancer FHACT® evaluation
Keck Medicine of USC DLBCL Genomic panel evaluation & optimization
Memorial Sloan-Kettering Cancer Ctr CLL, DLBCL, FL, MCL, Kidney Multiple collaborations
Moffitt Cancer Center CINV and PGx Prediction of Side Effects Associated With Chemo
National Cancer Institute Cervical Cancer FHACT® development
North Shore LIJ Health System CLL/SLL CLL/SLL validation & BTK inhibitor resistance
Stanford University DLBCL Risk stratification
University of Alabama Central Nervous System Lymphoma Biomarker investigation
University of Iowa Cancer Center Cervical Cancer, DLBCL FHACT® evaluation & MatBA®-DLBCL validation
Westchester Medical Center Central Nervous System Lymphoma Genomic biomarker identification using UroGenRA®
COLLABORATIONS WITH PREMIER CANCER RESEARCH
INSTITUTIONS
21. INVESTOR PRESENTATION | 2015 CANCER GENETICS, INC. | WWW.CANCERGENETICS.COM | @CANCER_GENETICS 21
CGI’S DISEASE-FOCUSED PATENT PORTFOLIO
Gynecological Cancers & Precancers
Chromosomal Analysis Using FISH
Gene Expression
Renal Cortical Neoplasms
Tissue of Origin
Mature B-Cell Neoplasms
HPV-Associated Cancers
2 US Patents | EU | India | Canada
Mature B-Cell Neoplasms
3 US Patents
Tissue of Origin*
2 US Patents | EU
Renal Cortical Neoplasms
13 US Patents | PCT | AU | CA | China | Japan
Gene Expression*
2 US Patents | Canada
Chromosomal Analysis Using FISH
2 US Applications Filed | PCT
Gynecological Cancers & Precancers
2 US Patents | PCT
HPV-Associated Cancers
* Acquired from Response Genetics. Transaction Pending
Through 2031
Through 2030
Through 2029
Through 2027
Through 2023
Through 2022
2 Patents
2 Patents
3 Patents
2 Patents
13 Patents
2 Patents
2 Filed
22. INVESTOR PRESENTATION | 2015 CANCER GENETICS, INC. | WWW.CANCERGENETICS.COM | @CANCER_GENETICS 22
DIVERSIFIED AND GROWING REVENUE BASE
55% 43%
2%
Full Year
2014
$10.2M
70% 25%
5%
1H
2015
$8.6M
CGI’s business is not over-dependent on third party
reimbursement. In 1H 2015, Medicare represented 6%
and other insurers represented 6% of consolidated
revenue.
• Entered into partnership with ICON to offer access to
ICON Laboratory Services combined with Cancer
Genetics' Focus::CLL™ chosen for global clinical trial
by leading biotechnology company
BIOPHARMA GLOBAL BIOTECH AND
PHARMACEUTICAL COMPANIES
• Launched new NGS panels, including Focus::Myeloid™
• Entered into preliminary agreement to acquire
Response Genetics (OTCQB:RGDX)
CLINICAL CANCER CENTERS, HOSPITALS,
REGIONAL LABS, AND CLINICIANS
• New research studies with leading cancer centers and
academic institutions
• Selected by regenerative medicine company,
ReproCELL, Inc., to provide (NGS) services
DISCOVERY PRECLINICAL RESEARCH GROUPS AT ACADEMIC,
GOVERNMENT & COMMERCIAL ORGANIZATIONS
23. INVESTOR PRESENTATION | 2015 CANCER GENETICS, INC. | WWW.CANCERGENETICS.COM | @CANCER_GENETICS 23
STRONG RECORD OF CONTINUOUS GROWTH
2011
2012
2013
20140
5
10
$10.2
$6.6
$4.3
$3.0
$10M
$5M
112%
BIOPHARMA REVENUE
GROWTH FROM 2013 to 2014
TOTAL REVENUE GREW FROM
$6.6M TO $10.2M
54% REVENUE GROWTH
FROM 2013 TO 2014
2013 2014
$0M
REVENUE GROWTH BY YEAR
24. INVESTOR PRESENTATION | 2015 CANCER GENETICS, INC. | WWW.CANCERGENETICS.COM | @CANCER_GENETICS 24
1H
2012
1H
2013
1H
2014
1H
20150
$8.6
$2.9
$3.1
$2.0
STRONG RECORD OF CONTINUOUS GROWTH
567%
BIOPHARMA REVENUE
GROWTH FROM 1H 2014
1H TOTAL REVENUE GREW FROM
$2.9M TO $8.6M
191% REVENUE GROWTH
FROM 1H 2014
2014 2015
$8M
$4M
$0M
FIRST HALF (1H) 2015 REVENUE GROWTH
25. INVESTOR PRESENTATION | 2015 CANCER GENETICS, INC. | WWW.CANCERGENETICS.COM | @CANCER_GENETICS 25
PROFORMA REVENUE WITH PROPOSED ACQUISITION
$5.2M
~$38M
ADDITIONAL REVENUE BACKLOG FROM
BIOPHARMA TRIALS
1H TOTAL REVENUE WOULD INCREASE
$8.6M TO
$16.3M
$34M to $40M
ANNUAL REVENUE RUN RATE
1H 2015 1H 2015 (Proforma)
2013 THRU FIRST HALF (1H) 2015 REVENUE
CGIX RESPONSE
0
5
10
15
20
25
30
FY13 FY14 1H -2015
$26.4M
Total
$26.9M
Total
$16.3M
1st Half
$19.8M $16.7M
$7.7M
$6.6M
$10.2M $8.6M
26. INVESTOR PRESENTATION | 2015 CANCER GENETICS, INC. | WWW.CANCERGENETICS.COM | @CANCER_GENETICS 26
STANDALONE SUMMARY STATEMENT OF OPERATIONS
SUMMARIZED INCOME STATEMENTS (dollars in thousands)
SUMMARIZED BALANCE SHEET (dollars in thousands)
1H, 2014 1H, 2015
REVENUE $2,942 8,555
Gross Profit 149 2,316
Gross Margin (%) 5% 27%
Research & Development 1,703 2,533
Sales & Marketing 1,667 2,300
General & Administrative 5,127 6,049
OPERATING PROFIT (Loss) ($8,348) ($8,566)
NET INCOME (Loss) ($6,673) ($9,258)
NON CASH ADJUSTMENTS $1,637 $2,812
NET INCOME (Loss) EXCLUDING NON CASH ITEMS + ($5,036) ($6,446)
Actual 06/30/15
ALL CASH* $23,744
STOCKHOLDERS’ EQUITY $26,772
* All cash includes $6,300 of restricted cash.
* $6,000 of that is now unrestricted as of May 7, 2015.
* (Cancer Genetics, Inc. 2014 YE 10Q, page 77)
+ This is non GAAP
+ measure – see slide 29
+ for computation
27. INVESTOR PRESENTATION | 2015 CANCER GENETICS, INC. | WWW.CANCERGENETICS.COM | @CANCER_GENETICS 27
HISTORICAL CLINICAL REIMBURSEMENT MIX
& PAYER COVERAGE
COVERED LIVES REPRESENTED BY
RECENT AGREEMENTS WITH
NATIONAL INTEGRATED NETWORKS
• America’s Choice Provider
• Blue Cross Blue Shield of California
• Blue Cross Blue Shield of Illinois
• Blue Cross Blue Shield of North Carolina
• Credentialing Organizations (NCQA, CAQH)
• Encore Health Network
• Harvard Pilgrim Health Plan
• Market-specific Medicaid plans (IL, CA, TX, FL, NY, NJ)
• Medicare Railroad
• MultiPlan
• TRICARE military plan
36%
29%
REGIONAL
AND NATIONAL
PAYERS
MEDICARE
COMMERCIAL
PAYERS
CGI PAYMENT HISTORY
(CLINICAL REVENUES ONLY)
35%
DIRECT BILL
MORE THAN
50M
28. INVESTOR PRESENTATION | 2015 CANCER GENETICS, INC. | WWW.CANCERGENETICS.COM | @CANCER_GENETICS 28
EXPERIENCED LEADERSHIP TEAM
Mandar Kulkarni, PhD
Chief Technology Officer, India
Randy Goodman, PhD
Director, Reimbursement & Clinical Revenue Cycle Management
20+ years of health economics, reimbursement, payer relations experience
Healthcare Mgmt Solutions, Scientia Advisors, ImpediMed
White House Healthcare Reform Policy Consultant to Presidents Clinton & Obama
Scott Clark, PhD
VP, Global QA & Biopharma Development
16+ years at pharma and clinical research companies
CAP Biorepository Director and oversees China operations
Gentris Corporation founding management team
Rob Fannon, MBA, MPH
VP, Biopharma Operations
10+ years operations, client mgmt, and molecular test & panel dev.
5 years in life science and pharmaceutical equity research
Roche Molecular Diagnostics, BioServe Biotechnologies, Ltd.
Steve Hepburn
EVP, Market Development, Biopharma Services
30+ years in the molecular diagnostics & clinical research arena
PPD, Omnicare Clinical Research, VivoMetrics, Quintiles
Launched Multiplexed ICE COLD-PCR(liquid biopsy platform)
Panna Sharma
Chief Executive Officer & President, Board Member
15+ years as advisor to global life science & healthcare companies
TSG Partners, iXL Enterprises, Interactive Solutions, Putnam Investment
Edward J. Sitar, CPA
Chief Financial Officer & Treasurer
Rita Shaknovich, MD, PhD
Group Medical Director & VP, Hematopathology Services
Jane Houldsworth, PhD
VP, Research & Development
25+ years in translational oncology research
MSKCC, CALTECH
Principal investigator of multiple Phases & Independent Investigator Award
Greg Ash
VP, Clinical Market Development
16+ years in the healthcare sector
Go Path Laboratories, Response Genetics, Eisai Oncology
Launched Halavan (treating metastatic breast cancer) & Marketing for Dacogen (MDS)
30+ years in finance & deal making in the healthcare industry
ActiveHealth Management (Aetna), Cadent, MIM Corp, Coopers & Lybrand (PWC)
10 transactions raising $150+ million, 12+ acquisition transactions
5+ years in both clinical (M/Z Dx) and genomic (Sandor LS) development
NIH grantee and two Young investigator awards
Scientific collaborations, business development, strategic alliances
15+ years in both clinical and research capacities
Weill Cornell Medial College, Mount Sinai Hospital, Columbia Presbyterian Hospital,
Albert Einstein Hospital
Head of Laboratory at Weill Cornell Medical College Heme Onc. Division
29. INVESTOR PRESENTATION | 2015 CANCER GENETICS, INC. | WWW.CANCERGENETICS.COM | @CANCER_GENETICS 29
COMPANY FACTS & BOARD OF DIRECTORS
SCIENTIFIC ADVISORY
BOARD
Andrea Califano, PhD
Timothy Chan, MD, PhD
Ahmet Dogan, MD, PhD
Riccardo Dalla-Favera, MD
Howard McLeod, PharmD
Vundavalli Murty, PhD
Hans-Guido Wendel, MD
Panna Sharma Michael J. Welsh, MD c, g
• Investigator at the Howard Hughes Medical Inst.
• Roy J. Carver Biomed Research Chair in Internal
Medicine & Molecular Physiology & Biophysics
• Director of Univ. of Iowa Inst. for Biomed Discovery
• CEO & president of Cancer Genetics
• General Manager of OncoSpire Genomics
• Previously managing partner/founder of TSG Partners
• 70+ buy & sell-side transactions (healthcare companies)
Howard McLeod, PharmD g Franklyn Prendergast, MD, PhD a, c, g
• Director of Mayo Clinic for Individualized Medicine
• Currently on boards of: Translational Genomics
Research Inst.; Infectious Disease Research Inst.;
DemeRx, Inc.; Ativa; Eli Lilly & Co.
• Personalized Medicine Medical Director at Moffitt
• Founding Director of the Univ. of NC Institute for
Pharmacogenomics (PGx) & Individualized Therapy
• 475+ peer-reviewed papers (PGx, applied therapeutics)
Raju S.K. Chaganti, PhD Geoffrey Harris, CFA a
• 30+ years experience as healthcare analyst &
portfolio manager for biotech/life sci companies
• Portfolio manager/managing partner at c7 Advisors
• Previously: Cantor Fitzgerald; Gleacher & Company
• Founded CGI & served as Chairman until 2014
• Internat’ly recognized leader in molecular genetics
• Co-discovered lymphoma & kidney cancer patents
• Incumbent of the William Snee E. Chair at MSKCC
John Pappajohn Non-Executive Chairman Ted Cannon a, c
• Founder & President of Clinical Research Center
of Cape Cod
• Previously at Franey Medical Labs; Pharmacia
Diagnostics; Alletess
• Involved in 100+ start-up companies
• Served as director of 40+ public companies
• Currently on boards of: American CareSource
Holdings; ConMed Healthcare Mgmt; CNS Response
For complete bios, see web link below:
cancergenetics.com/about-cgi/scientific-advisor/
NASDAQ: CGIX
MARKET CAP: 110.55 M
AUDITORS: McGladrey LLP
LEGAL: Lowenstein Sandler LLP
a: Audit Committee c: Compensation Committee g: Governance and Nominating Committee
30. INVESTOR PRESENTATION | 2015 CANCER GENETICS, INC. | WWW.CANCERGENETICS.COM | @CANCER_GENETICS 30
CONSISTENT ACHIEVEMENT OF MILESTONES EXPECTED
IN COMING QUARTERS
REIMBURSEMENT & MARKET ADOPTION
• Increasing covered lives market access through add’l payers & health care organizations
• Additional international agreements for FHACT® distribution and co-marketing
partnerships in key geographies
NEXT GENERATION SEQUENCING PANELS
• Launching multi-marker NGS panel for lymphoid malignancies
• Multiple Myeloma NGS panel launch, Oncospire Second half of 2015
DATA TO SUPPORT PRODUCTS
• Lymphoid, Myeloid and CLL Panels - Additional data and results to support clinical usage, patient value and payor coverage
• FHACT® - Additional data from a study conducted in conjunction with NCI and more published papers focused on FHACT®,
including a health economic study
BIOPHARMA REVENUES & MARKET SHARE
• Additional news on biopharma partners & relationships
• Major collaborations with US & Asia biopharma companies
LATE PHASES OF FINALIZING SIGNIFICANT PARTNERSHIPS TO EXPAND BIOPHARMA BUSINESS
31. INVESTOR PRESENTATION | 2015 CANCER GENETICS, INC. | WWW.CANCERGENETICS.COM | @CANCER_GENETICS 31
CANCER GENETICS, INC. INVESTOR HIGHLIGHTS
Uniquely Positioned
to Address Global
Market Opportunities
in Oncology
3 ACQUISITIONS
$458B GLOBAL ONCOLOGY
SPENT BY 2030
Unique &
Proprietary Portfolio
of Genomic
Tests & Panels
8 PATENTS
9 TESTS LAUNCHED
Strong & Growing
Relationships with
Leading Biotech &
Pharma Partners
+650%
BIOPHARMA
CONTRACTS
2012-2015
18 RESEARCH
COLLABORATIONS
Innovation &
Expertise Driven
by Key
Collaborations
100+ CUMULATIVE YEARS
OF EXPERIENCE
World-Class
Management
Team & Scientific
Advisory Board
55% AAGR
Diversified &
High Growth
Revenue
Streams
32. THE ONCOLOGY
DIAGNOSTICS
PARTNER FROM
BENCH TO BEDSIDE
CGI Headquarters
201 Route 17 North, 2nd Fl.
Rutherford, NJ 07070
Phone: +1 201-528-9200
Fax: +1 201-528-9235
RUTHERFORD, NJ
Research Triangle Park
133 Southcenter Court, S.400
Morrisville, NC 27569
Phone: +1 919-465-0100
Fax: +1 919-465-0554
RALEIGH, NC
#3-1-135 / 1A CNR Complex
Mallapur Main Road, R.R. Dst.
Hyderabad – 500 076, Telangana
Toll-free: +91 040-2717-8178
Fax: +91 040-2717-8176
HYDERABAD, INDIA
781 Cai Lun Road, Room 803
Shanghai 201203
P.R. China
Toll-free: +91 040-2717-8178
Fax: +91 040-2717-8176
SHANGHAI, CHINA
WWW.CGIX.COM
WWW.CANCERGENETICS.COM
